Overview
Malignant and benign tumors of the brain, spine and base of skull. Mathematical modelling of tumor metabolism, mass transfer and the response to ionizing radiation. Enhancing clinical outcome in stereotactic radiosurgery, fractionated stereotactic radiotherapy and stereotactic body radiotherapy.
Current Duke Appointments & Affiliations
Professor of Radiation Oncology
·
2018 - Present
Radiation Oncology,
Clinical Science Departments
Professor in Neurosurgery
·
2018 - Present
Neurosurgery,
Neurosurgery
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases.
Journal article Adv Radiat Oncol · November 2026 PURPOSE: Radionecrosis (RN) is a dose-limiting toxicity after stereotactic radiosurgery (SRS) for brain metastases and is hard to differentiate from treated tumor progression. The outcomes of patients with RN following SRS are poorly described, particularl ... Full text Link to item CiteAn Explainable Deep Model for Risk Scoring and Accurate Radionecrosis Identification Following Brain Metastasis Stereotactic Radiosurgery.
Conference Int J Radiat Oncol Biol Phys · June 1, 2026 PURPOSE: As survival improves for patients with brain metastases (BM), distinguishing local recurrence (LR) from radionecrosis (RN) is a growing neuro-oncologic challenge. We aimed to develop an explainable deep learning model to noninvasively distinguish ... Full text Link to item CiteComparison of Local Medicare Guidance and Medicare Advantage Plans for Stereotactic Radiosurgery for Brain Metastases.
Journal article Adv Radiat Oncol · February 2026 PURPOSE: Medicare Advantage operates under a capitated payment model, where Medicare Advantage Organizations (MAOs) must provide services that meet or exceed Medicare Parts A and B standards, ensuring actuarial equivalence. MAOs are mandated to base their ... Full text Link to item CiteRecent Grants
PHASE 1, SINGLE-CENTER, DOSE-ESCALATING, OPEN-LABEL, SAFETY CLINICAL TRIAL OF PARENTERAL ASCORBATE-MEGLUMINE AS A NOVEL MAGNETIC RESONANCE IMAGING-GUIDED ADJUNCTIVE THERAPEUTIC FOR STEREOTACTIC RADIOSURGERY
Clinical TrialPrincipal Investigator · Awarded by LadeRx · 2023 - 2027BMX-001 AS A THERAPEUTIC AGENT FOR TREATMENT OF MULTIPLE BRAIN METASTASES
Clinical TrialPrincipal Investigator · Awarded by BioMimetix JV LLC · 2018 - 2023Developing knowledge models to enable rapid learning in radiation therapy
ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020View All Grants
Education
University of Texas Health Science Center San Antonio ·
1999
M.D.
Rice University ·
1978
Ph.D.